AU2020394255B2 - Long-acting GDF15 fusion protein and pharmaceutical composition comprising same - Google Patents
Long-acting GDF15 fusion protein and pharmaceutical composition comprising sameInfo
- Publication number
- AU2020394255B2 AU2020394255B2 AU2020394255A AU2020394255A AU2020394255B2 AU 2020394255 B2 AU2020394255 B2 AU 2020394255B2 AU 2020394255 A AU2020394255 A AU 2020394255A AU 2020394255 A AU2020394255 A AU 2020394255A AU 2020394255 B2 AU2020394255 B2 AU 2020394255B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- gdf15
- amino acid
- hole
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190153680 | 2019-11-26 | ||
| KR10-2019-0153680 | 2019-11-26 | ||
| PCT/KR2020/016842 WO2021107603A2 (en) | 2019-11-26 | 2020-11-25 | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020394255A1 AU2020394255A1 (en) | 2022-06-09 |
| AU2020394255B2 true AU2020394255B2 (en) | 2026-08-06 |
Family
ID=76130664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020394255A Active AU2020394255B2 (en) | 2019-11-26 | 2020-11-25 | Long-acting GDF15 fusion protein and pharmaceutical composition comprising same |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230002460A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4065597A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023503472A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210065057A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114729020A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020394255B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022010227A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3161302A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006173A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021107603A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202204624B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4351627A4 (en) * | 2021-05-21 | 2025-06-04 | Yuhan Corporation | COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST |
| AU2022278933A1 (en) * | 2021-05-21 | 2023-12-07 | Yuhan Corporation | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant |
| US20240350588A1 (en) * | 2021-08-24 | 2024-10-24 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and use thereof |
| EP4619423A1 (en) * | 2022-11-18 | 2025-09-24 | Yuhan Corporation | Dual function proteins and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160120999A1 (en) * | 2014-10-31 | 2016-05-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| WO2016069925A1 (en) * | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| DK2441466T3 (da) | 2004-04-13 | 2014-10-27 | St Vincents Hosp Sydney | MIC-1-inhiberende middel |
| EP1861419B1 (en) * | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| ES2627337T3 (es) * | 2010-08-26 | 2017-07-27 | F. Hoffmann-La Roche Ag | Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| CA2899170C (en) * | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) * | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| LT3027642T (lt) * | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| WO2015197446A1 (en) * | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| JP6704358B2 (ja) * | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR101727506B1 (ko) * | 2016-07-14 | 2017-05-04 | 충남대학교 산학협력단 | Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물 |
-
2020
- 2020-11-25 CA CA3161302A patent/CA3161302A1/en active Pending
- 2020-11-25 KR KR1020200160013A patent/KR20210065057A/ko active Pending
- 2020-11-25 EP EP20892374.8A patent/EP4065597A4/en active Pending
- 2020-11-25 JP JP2022530716A patent/JP2023503472A/ja active Pending
- 2020-11-25 MX MX2022006173A patent/MX2022006173A/es unknown
- 2020-11-25 WO PCT/KR2020/016842 patent/WO2021107603A2/en not_active Ceased
- 2020-11-25 US US17/779,932 patent/US20230002460A1/en active Pending
- 2020-11-25 BR BR112022010227A patent/BR112022010227A2/pt unknown
- 2020-11-25 AU AU2020394255A patent/AU2020394255B2/en active Active
- 2020-11-25 CN CN202080081137.8A patent/CN114729020A/zh active Pending
-
2022
- 2022-04-25 ZA ZA2022/04624A patent/ZA202204624B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016069925A1 (en) * | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| US20160120999A1 (en) * | 2014-10-31 | 2016-05-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4065597A4 (en) | 2024-01-24 |
| CA3161302A1 (en) | 2021-06-03 |
| CN114729020A (zh) | 2022-07-08 |
| JP2023503472A (ja) | 2023-01-30 |
| EP4065597A2 (en) | 2022-10-05 |
| MX2022006173A (es) | 2022-06-14 |
| WO2021107603A2 (en) | 2021-06-03 |
| WO2021107603A3 (en) | 2021-07-15 |
| ZA202204624B (en) | 2023-11-29 |
| KR20210065057A (ko) | 2021-06-03 |
| BR112022010227A2 (pt) | 2022-09-13 |
| US20230002460A1 (en) | 2023-01-05 |
| AU2020394255A1 (en) | 2022-06-09 |